- Home
- GP vs CANF Comparison
GP vs CANF Comparison
Compare GP & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GP | CANF |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | Canada | Israel |
| Employees | 113 | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.0M |
| IPO Year | 2013 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GP | CANF |
|---|---|---|
| Price | $1.22 | $3.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 169.4K | 19.5K |
| Earning Date | 02-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.17 |
| 52 Week High | $4.00 | $10.40 |
Technical Indicators
Market Signals| Indicator | GP | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 47.56 |
| Support Level | $1.02 | $2.87 |
| Resistance Level | $1.37 | $3.24 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 55.26 | 55.56 |
Price Performance
Historical ComparisonAbout GP GreenPower Motor Company Inc.
GreenPower Motor Co Inc is the manufacturer and distributor of all-electric charter, school, and city buses. The company offers electric-powered transit buses deploying electric drive and battery technologies with a lightweight chassis and low-floor body. Its product line includes all-electric transit buses, all-electric school buses, and shuttle buses. The company's buses depend on clean sheet design and utilize a custom battery management system and a proprietary flex power system for the drive motors. Geographically, the company generates a majority of its revenue from the United States of America and the rest from Canada.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.